Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Probi AB (publ)    PROB   SE0001280355

PROBI AB (PUBL)

(PROB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector news

Probi publ : A true pioneer in probiotic research is elected NutraChampion 2020

share with twitter share with LinkedIn share with facebook
05/14/2020 | 02:01am EDT

Bengt Jeppsson, one of the founders of Probi[®], elected NutraChampion winner

Yesterday, Dr. Bengt Jeppsson was selected as the winner of the new NutraChampion category of Nutra Ingredients Awards. The jury's selection was judged as "An important and lasting contribution to our industry and the wider causes of public health and nutrition, this award celebrates long-term and high-level personal achievements that have driven change within the science and business of our industry".

"It all started with a vision of saving lives" is the opening sentence often used by Professor Jeppsson when talking about his discovery of the probiotic bacteria Lactobacillus plantarum 299v (LP299V[®]).

Bengt Jeppsson, Professor and Medical Doctor, was Sweden's first probiotic pioneer and one of the very first scientists to go beyond standard medical treatments.

Dr Jeppsson began his work at Lund University Hospital in Sweden, in the 1980s. He identified a huge problem: patients in the intensive care unit (ICU) often suffered from sepsis and major organ failure during recovery. Collaborative research led by Dr Jeppsson discovered one of today's most researched probiotic bacteria, LP299V[®], and its important role in promoting gastrointestinal health in persons who need it the most. The initial studies on the LP299V[®] strain showed great support for improved recovery and health.

Since then, the LP299V[®] bacterium has been studied in more than 60 clinical studies and is today one of the leading probiotic strains to support digestive health, sold in more than 40 markets over the world.Bengt Jeppsson remains active as Professor, Medical Doctor and Senior Scientific Advisor at Probi[®] and in regards to the award he comments: "I am very pleased and see the award as an acknowledgement of a lifetime dedication to probiotic research - the award is shared with all the people who made it possible". And Bengt concludes: "My passion is to see how we can use bacteria as friends and not as enemies".

 

FOR FURTHER INFORMATION, CONTACT:

Charlotte Beyerholm, Director Marketing & Global Communication, Probi[®], tel +46 76 870 94 65, e-mail: charlotte.beyerholm@probi.com

ABOUT PROBI

Probi is a world leader within probiotics. Our vision is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Probi offers dedicated probiotic expertise and partnership all the way from R&D to finished products for companies within the consumer healthcare and food industry. Our GMP certified manufacturing facilities produce probiotics in custom made formats with value-adding delivery technologies. Founded by scientists in Sweden 1991, Probi is a multinational company with 4 centers of excellence, active in more than 40 markets around the world and holding over 400 patents worldwide. Read more at www.probi.com.

https://news.cision.com/probi/r/a-true-pioneer-in-probiotic-research-is-elected-nutrachampion-2020,c3109913

https://mb.cision.com/Main/1556/3109913/1247455.pdf

https://news.cision.com/probi/i/bengtjeppssonlabb2,c2784979

(c) 2020 Cision. All rights reserved., source Press Releases - English

Stocks mentioned in the article
ChangeLast1st jan.
PROBI AB (PUBL) -1.30% 342.5 Delayed Quote.54.28%
SYMRISE AG -0.42% 117.75 Delayed Quote.25.53%
share with twitter share with LinkedIn share with facebook
All news about PROBI AB (PUBL)
08/27PROBI : New clinical results on stress from Probi and their probiotic strain L. ..
AQ
07/17Q2 2020 : Probi raises long-term financial targets
AQ
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
PU
07/14PROBI PUBL : Presentation of Probi's Q2 report 2020 and new financial targets
AQ
07/02PROBI PUBL : and Örebro University to collaborate on research into exploration o..
AQ
05/14PROBI PUBL : A true pioneer in probiotic research is elected NutraChampion 2020
AQ
05/14PROBI AB (PUBL) : Ex-dividend day for final dividend
FA
05/13PROBI PUBL : ´s Annual General Meeting 2020
PU
05/13PROBI PUBL : Annual General Meeting 2020
AQ
04/24Q1 2020 : A solid start to the year
AQ
More news
Financials
Sales 2020 671 M 73,4 M 73,4 M
Net income 2020 92,0 M 10,1 M 10,1 M
Net cash 2020 284 M 31,1 M 31,1 M
P/E ratio 2020 41,5x
Yield 2020 0,45%
Capitalization 3 902 M 427 M 427 M
EV / Sales 2020 5,40x
EV / Sales 2021 4,88x
Nbr of Employees -
Free-Float 38,9%
Chart PROBI AB (PUBL)
Duration : Period :
Probi AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROBI AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 2
Average target price 420,00 SEK
Last Close Price 342,50 SEK
Spread / Highest target 22,6%
Spread / Average Target 22,6%
Spread / Lowest Target 22,6%
EPS Revisions
Managers
NameTitle
Tom Juhani Rönnlund Chief Executive Officer
Jean-Yves Parisot Chairman
Andy McShea Vice President-Operations
Henrik Lundkvist Chief Financial Officer
Niklas Brandt Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
PROBI AB (PUBL)54.28%427
BY-HEALTH CO., LTD.26.76%4 785
BALCHEM CORPORATION-5.88%3 094
THE SIMPLY GOOD FOODS COMPANY-23.72%2 076
MEDIFAST, INC.50.48%1 931
JAMIESON WELLNESS INC.55.88%1 187